IDEXX Laboratories, Inc. Insider Trading

IDXX

Last 12 months

Insiders sold $37.7M and bought nothing on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. President and CEO Jonathan Jay Mazelsky sold $15.3M on Feb 26, 22% of their stake, outside a plan. The last open-market buy by an executive or director was in Aug 2019.

Net open-market

−$37.7M

0 buys · 8 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

0 / 6

executives and directors

Last open-market buy

Aug 2019

Aug 6, 2019

Get an email when IDXX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 4	Lawrence D Kingsley Director	SoldNo plan	2,203	$532.08	$1.17M	19%	Form 4
Mar 3	Nimrata Hunt Executive Vice President	SoldNo plan	1,758	$634.57	$1.12M	8.8%	Form 4
Feb 26	Jonathan Jay Mazelsky President and CEO	SoldNo plan 13 parts	23,326	$657.55 average	$15.3M	22%	Form 4
Feb 26	Nimrata Hunt Executive Vice President	SoldNo plan	2,693	$661.54	$1.78M	12%	Form 4
Feb 17	Michael G Erickson Executive Vice President	SoldNo plan 6 parts	5,371	$627.38 average	$3.37M	26%	Form 4
Feb 17	Sophie V. Vandebroek Director	SoldNo plan 2 parts	1,464	$628.62 average	920K	14%	Form 4
Feb 10	George Fennell Executive Vice President	SoldNo plan 8 parts	11,345	$646.72 average	$7.34M	54%	Form 4
Nov 7, 2025	Nimrata Hunt Executive Vice President	SoldNo plan 4 parts	9,425	$703.34 average	$6.63M	31%	Form 4
Aug 22, 2025	M Anne Szostak Director	SoldNo plan	2,187	$647.33	$1.42M	81%	Form 4
Aug 12, 2025	Michael G Erickson Executive Vice President	SoldNo plan 2 parts	406	$649.96 average	264K	3.5%	Form 4
Aug 11, 2025	Nimrata Hunt Executive Vice President	SoldNo plan	1,200	$656.53	788K	6.2%	Form 4
Aug 8, 2025	Sharon E. Underberg EVP, GC & Corporate Secretary	SoldNo plan	5,450	$651.60	$3.55M	46%	Form 4
Aug 6, 2025	Nimrata Hunt Executive Vice President	SoldNo plan 3 parts	7,143	$630.43 average	$4.5M	28%	Form 4
Aug 6, 2025	Jonathan Jay Mazelsky President and CEO	SoldNo plan 10 parts	29,260	$631.98 average	$18.5M	26%	Form 4
Aug 6, 2025	Michael Lane Executive Vice President	SoldNo plan 3 parts	8,411	$627.73 average	$5.28M	52%	Form 4
May 21, 2025	M Anne Szostak Director	SoldNo plan 2 parts	2,306	$512.98 average	$1.18M	53%	Form 4
May 13, 2025	Daniel M Junius Director	SoldNo plan	2,683	$506.41	$1.36M	45%	Form 4
May 9, 2025	Sophie V. Vandebroek Director	SoldNo plan	1,279	$491.34	628K	12%	Form 4
Feb 10, 2025	George Fennell Executive Vice President	SoldNo plan	9,986	$462.53	$4.62M	55%	Form 4
Feb 7, 2025	M Anne Szostak Director	SoldNo plan	3,000	$465.95	$1.4M	49%	Form 4
Nov 27, 2024	Sophie V. Vandebroek Director	SoldNo plan	344	$420.44	145K	28%	Form 4

Sep 4No plan
Lawrence D Kingsley
Director · sold 2,203 at $532.08
$1.17M
19% of stake
Mar 3No plan
Nimrata Hunt
Executive Vice President · sold 1,758 at $634.57
$1.12M
8.8% of stake
Feb 26No plan
Jonathan Jay Mazelsky
President and CEO · sold 23,326 at avg $657.55
$15.3M
22% of stake
Feb 26No plan
Nimrata Hunt
Executive Vice President · sold 2,693 at $661.54
$1.78M
12% of stake
Feb 17No plan
Michael G Erickson
Executive Vice President · sold 5,371 at avg $627.38
$3.37M
26% of stake
Feb 17No plan
Sophie V. Vandebroek
Director · sold 1,464 at avg $628.62
920K
14% of stake
Feb 10No plan
George Fennell
Executive Vice President · sold 11,345 at avg $646.72
$7.34M
54% of stake
Nov 7, 2025No plan
Nimrata Hunt
Executive Vice President · sold 9,425 at avg $703.34
$6.63M
31% of stake
Aug 22, 2025No plan
M Anne Szostak
Director · sold 2,187 at $647.33
$1.42M
81% of stake
Aug 12, 2025No plan
Michael G Erickson
Executive Vice President · sold 406 at avg $649.96
264K
3.5% of stake
Aug 11, 2025No plan
Nimrata Hunt
Executive Vice President · sold 1,200 at $656.53
788K
6.2% of stake
Aug 8, 2025No plan
Sharon E. Underberg
EVP, GC & Corporate Secretary · sold 5,450 at $651.60
$3.55M
46% of stake
Aug 6, 2025No plan
Nimrata Hunt
Executive Vice President · sold 7,143 at avg $630.43
$4.5M
28% of stake
Aug 6, 2025No plan
Jonathan Jay Mazelsky
President and CEO · sold 29,260 at avg $631.98
$18.5M
26% of stake
Aug 6, 2025No plan
Michael Lane
Executive Vice President · sold 8,411 at avg $627.73
$5.28M
52% of stake
May 21, 2025No plan
M Anne Szostak
Director · sold 2,306 at avg $512.98
$1.18M
53% of stake
May 13, 2025No plan
Daniel M Junius
Director · sold 2,683 at $506.41
$1.36M
45% of stake
May 9, 2025No plan
Sophie V. Vandebroek
Director · sold 1,279 at $491.34
628K
12% of stake
Feb 10, 2025No plan
George Fennell
Executive Vice President · sold 9,986 at $462.53
$4.62M
55% of stake
Feb 7, 2025No plan
M Anne Szostak
Director · sold 3,000 at $465.95
$1.4M
49% of stake
Nov 27, 2024No plan
Sophie V. Vandebroek
Director · sold 344 at $420.44
145K
28% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch IDXX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

In Vitro & In Vivo Diagnostic Substances · Pick stocks to compare with IDXX

CompareIntrinsic value

QDELQuidelOrtho Corporation

$14.35+1.85%0

LNTHLantheus Holdings, Inc.

$101.14+0.34%92

NEOGNeogen Corporation

$12.45+2.89%15

MYGNMyriad Genetics Inc.

$6.02-0.33%23

JAZZJazz Pharmaceuticals plc

$234.66+2.14%58

ELANElanco Animal Health Incorporated

$25.31+3.01%46

PRGOPerrigo Company plc

$15.83+0.83%17

ALNYAlnylam Pharmaceuticals Inc

$161.08+0.74%81

Held by ETFs

IDXX is in 338 US ETFs. The largest of them, with IDXX's weight in each:

Spot a number that looks wrong? Check it in IDXX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing IDXX

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.